This result is in line with that of the previous research conducted by Wang et al. In their cohort study, they noted that the combination of TCM and EGFR-tyrosine kinase inhibitors (EGFR-TKIs) significantly extended PFS and OS among patients with NSCLC with EGFR mutations [20]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.